Carboplatin + Cetuximab + Docetaxel

This is a combination chemotherapy regimen consisting of carboplatin (a platinum-based chemotherapy agent), cetuximab (a monoclonal antibody targeting EGFR), and docetaxel (a taxane chemotherapy agent). The combination has been studied in clinical trials for various cancer types, particularly non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (SCCHN). The three agents in this combination work through different but complementary mechanisms: - **Carboplatin**: Forms DNA adducts leading to apoptosis - **Cetuximab**: Promotes cell cycle arrest and activates proapoptotic molecules by targeting the epidermal growth factor receptor (EGFR) - **Docetaxel**: Inhibits microtubule disassembly, preventing cell division These properties suggest that the three agents combined may have highly additive proapoptotic and antitumor growth effects via different molecular pathways, attacking more targets within heterogeneous tumors. A phase 2 study evaluated this combination in chemotherapy-naïve patients with stage IIIB (with effusion) or stage IV NSCLC. Patients received cetuximab (400 mg/m² on Day 1 and 250 mg/m² on Days 8 and 15) plus docetaxel (75 mg/m² on Day 1) and carboplatin (AUC=6 on Day 1) every 21 days for up to 6 cycles. After completing the combination therapy, patients without disease progression continued on single-agent cetuximab for up to 1 year or until disease progression. The study enrolled 80 patients, with a median of 4 treatment cycles administered. Results showed: - Objective response rate: 15.2% - Median progression-free survival: 4.6 months - Median overall survival: 10.3 months Common grade 3-4 adverse events included neutropenia (30%), hypotension (3%), hypokalemia (4%), and hypomagnesemia (3%). Different administration schedules have been used in clinical trials: 1. **Every 3 weeks regimen**: - Carboplatin AUC 5 or 6 on day 1 - Docetaxel 75 mg/m² on day 1 - Cetuximab 400 mg/m² loading dose, then 250 mg/m² weekly 2. **Weekly regimen**: - Carboplatin AUC 2 weekly (maximum dose 220 mg) - Paclitaxel 80 mg/m² weekly - Cetuximab 400 mg/m² loading dose, then 250 mg/m² weekly After completing the combination therapy (typically 4-6 cycles), patients without disease progression often continue on single-agent cetuximab maintenance therapy until disease progression or unacceptable toxicity. This combination showed "modest anticancer activity" in NSCLC with an "acceptable toxicity profile".